Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X7DZ
|
|||
| Drug Name |
Pyrazolo[1,5-a]pyrimidine derivative 1
|
|||
| Synonyms |
PMID26161824-Compound-131
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Patented | [1] | |
| Company |
Mitsubishi Tanabe Pharma Corporation MORITANI, Yasunori SHIRAI, Kimihiro OI, Marik
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H22Cl2N4O
|
|||
| Canonical SMILES |
C1CCC(CC1)NC(=O)C2=C3N=CC(=C(N3N=C2)C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
|
|||
| InChI |
1S/C25H22Cl2N4O/c26-17-12-10-16(11-13-17)23-20(19-8-4-5-9-22(19)27)14-28-24-21(15-29-31(23)24)25(32)30-18-6-2-1-3-7-18/h4-5,8-15,18H,1-3,6-7H2,(H,30,32)
|
|||
| InChIKey |
ZZBARLOXOSWJIH-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Antagonist | [1] |
| Target's Patent Info | Cannabinoid receptor 1 (CB1) | Target's Patent Info | [1] | |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.